共 50 条
Impact of operative start time on surgical outcomes in patients undergoing primary cytoreduction for advanced ovarian cancer
被引:20
|作者:
Tanner, Edward J.
[1
]
Long, Kara C.
[1
]
Zhou, Qin
[2
]
Brightwell, Rachel M.
[1
]
Gardner, Ginger J.
[1
]
Abu-Rustum, Nadeem R.
[1
]
Leitao, Mario M., Jr.
[1
]
Sonoda, Yukio
[1
]
Barakat, Richard R.
[1
]
Iasonos, Alexia
[2
]
Chi, Dennis S.
[1
]
机构:
[1] Mem Sloan Kettering Canc Ctr, Dept Surg, Gynecol Serv, New York, NY 10065 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Biostat, New York, NY 10065 USA
关键词:
Cytoreductive surgery;
Advanced ovarian cancer;
Operative start time;
QUALITY-IMPROVEMENT;
SLEEP-DEPRIVATION;
SURGERY;
SURVIVAL;
MORBIDITY;
PERFORMANCE;
CARCINOMA;
DISEASE;
PART;
D O I:
10.1016/j.ygyno.2012.04.014
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
Objectives. To evaluate the impact of operative start time (OST) on surgical outcomes in patients with advanced ovarian cancer. Methods. All stage IIIB-IV serous ovarian cancer patients who underwent primary surgery at our institution from 1/01 to 1/10 were identified. Fourteen factors were evaluated for an association with surgical outcomes including OST and OR tumor index (1 point each for carcinomatosis and/or bulky [>= 1 cm] upper abdominal disease). Univariate logistic regression considering within-surgeon clustering was performed for cytoreduction to <= 1 cm versus > 1 cm residual disease. In patients with <= 1 cm residual disease, univariate logistic regression considering within-surgeon clustering was performed for 1-10 mm residual disease versus complete gross resection (CGR, 0 mm residual). A multivariate logistic model was developed based on univariate analysis results in the <= 1 cm residual disease cohort. Results. Of 422 patients, residual disease was: 0 mm, 144 (34.1%); 1-10 mm, 175 (41.5%); > 10 mm, 103 (23.3%). OST was not associated with cytoreduction to <= 1 cm residual disease on univariate analysis. In the <= 1 cm residual disease cohort, albumin, CA-125, ascites, ASA score, stage, OR tumor index, and OST were associated with CGR on univariate analysis. Earlier OSTs were associated with increased rates of CGR. On multivariate analysis, CA-125 was independently associated with CGR. OST was associated with CGR in patients with an OR tumor index of 2 but not an OR tumor index < 2. Conclusions. OST was not associated with cytoreduction to <= 1 cm residual disease in patients with advanced serous ovarian cancer. In the cohort of patients with <= 1 cm residual disease, later OSTs were associated with reduced rates of CGR in patients with greater tumor burden. (c) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码:58 / 63
页数:6
相关论文